FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980814527> ?p ?o ?g. }

• W2980814527 abstract "Abstract Background Durable tumor regression can be achieved in Multiple Myeloma (MM) patients by immunotherapeutic approaches, such as allogeneic stem cell transplantation and donor lymphocyte infusion. However, the low rate of patients, who reach a sustained remission, impedes the success of this therapeutic approach. Currently, much emphasis is placed on the role of the tumor microenvironment in tumor cell immune escape. We previously described that different accessory cells of the microenvironment significantly inhibited the lysis of MM cell lines by T cells in a cell-cell contact dependent manner. Further analysis revealed that this immune escape could be attributed to the induction of a cell adhesion-mediated immune resistance (CAM-IR) of MM against T cell lysis in vitro. Further in vitro studies identified up-regulation of survivin in the MM cells as one of the potential mechanisms of immune resistance. Moreover, co-culture with YM155, a small molecule survivin suppressant, could abrogate accessory cell induced resistance in vitro. Methods and Results We investigated the influence of a human bone marrow microenvironment on the anti tumor activity of T cell therapy in a human-mouse hybrid model (Groen et al. Blood 2012). Immune-deficient RAG2-/- γc-/- -mice were implanted subcutaneously either with uncoated scaffolds or scaffolds coated with human mesenchymal stromal cells (MSC), which generates a human bone marrow environment. Luciferase transduced MM cell line UM9 injected directly in both types of scaffolds grew into MM tumors and were treated with Myeloma reactive minor Histocompatibility antigen specific T cell clones. The T cells induced effective anti-myeloma responses against tumors developed in the uncoated scaffolds. In contrast, and consistent with the in vitro results, no anti-tumor effect was observed in the MSC coated scaffolds. Thus confirming in vivo a microenvironment induced resistance of MM cells to T cell kill. We next investigated if the resistance could be abrogated by combination therapy with T cells and YM155.To this end, mice with tumors in human MSC coated scaffolds were treated with T cells alone, YM155 alone, or the combination of both. YM155- nor T cell-monotherapy induced tumor regression on evaluation of tumor growth based on bioluminescent signal. Moreover, the combination of YM155 with T cells demonstrated a substantial anti-tumor effect. Conclusion YM155 treatment can sensitize myeloma cells to T cell mediated anti-tumor effects and more importantly can overcome microenvironment-mediated resistance of MM cells to T cell treatment. These findings support further development of CAM-IR modulating agents in combination with immune therapy. Disclosures: Minnema: Janssen Cilag: Consultancy, Honoraria. Lokhorst:Genmab A/S: Consultancy, Research Funding; Celgene: Honoraria; Johnson-Cilag: Honoraria; Mudipharma: Honoraria." @default.
• W2980814527 created "2019-10-25" @default.
• W2980814527 creator A5012712111 @default.
• W2980814527 creator A5049413660 @default.
• W2980814527 creator A5050381297 @default.
• W2980814527 creator A5058429057 @default.
• W2980814527 creator A5060212042 @default.
• W2980814527 creator A5077647224 @default.
• W2980814527 creator A5080836916 @default.
• W2980814527 creator A5085791878 @default.
• W2980814527 date "2013-11-15" @default.
• W2980814527 modified "2023-09-28" @default.
• W2980814527 title "The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model" @default.
• W2980814527 doi "https://doi.org/10.1182/blood.v122.21.3250.3250" @default.
• W2980814527 hasPublicationYear "2013" @default.
• W2980814527 type Work @default.
• W2980814527 sameAs 2980814527 @default.
• W2980814527 citedByCount "0" @default.
• W2980814527 crossrefType "journal-article" @default.
• W2980814527 hasAuthorship W2980814527A5012712111 @default.
• W2980814527 hasAuthorship W2980814527A5049413660 @default.
• W2980814527 hasAuthorship W2980814527A5050381297 @default.
• W2980814527 hasAuthorship W2980814527A5058429057 @default.
• W2980814527 hasAuthorship W2980814527A5060212042 @default.
• W2980814527 hasAuthorship W2980814527A5077647224 @default.
• W2980814527 hasAuthorship W2980814527A5080836916 @default.
• W2980814527 hasAuthorship W2980814527A5085791878 @default.
• W2980814527 hasConcept C16930146 @default.
• W2980814527 hasConcept C185592680 @default.
• W2980814527 hasConcept C203014093 @default.
• W2980814527 hasConcept C2776090121 @default.
• W2980814527 hasConcept C2776107976 @default.
• W2980814527 hasConcept C2776156784 @default.
• W2980814527 hasConcept C2780007613 @default.
• W2980814527 hasConcept C502942594 @default.
• W2980814527 hasConcept C86803240 @default.
• W2980814527 hasConcept C8891405 @default.
• W2980814527 hasConceptScore W2980814527C16930146 @default.
• W2980814527 hasConceptScore W2980814527C185592680 @default.
• W2980814527 hasConceptScore W2980814527C203014093 @default.
• W2980814527 hasConceptScore W2980814527C2776090121 @default.
• W2980814527 hasConceptScore W2980814527C2776107976 @default.
• W2980814527 hasConceptScore W2980814527C2776156784 @default.
• W2980814527 hasConceptScore W2980814527C2780007613 @default.
• W2980814527 hasConceptScore W2980814527C502942594 @default.
• W2980814527 hasConceptScore W2980814527C86803240 @default.
• W2980814527 hasConceptScore W2980814527C8891405 @default.
• W2980814527 hasLocation W29808145271 @default.
• W2980814527 hasOpenAccess W2980814527 @default.
• W2980814527 hasPrimaryLocation W29808145271 @default.
• W2980814527 hasRelatedWork W1952114414 @default.
• W2980814527 hasRelatedWork W2001177982 @default.
• W2980814527 hasRelatedWork W2004543856 @default.
• W2980814527 hasRelatedWork W2140226967 @default.
• W2980814527 hasRelatedWork W2155339987 @default.
• W2980814527 hasRelatedWork W2342907620 @default.
• W2980814527 hasRelatedWork W2537973974 @default.
• W2980814527 hasRelatedWork W2555518604 @default.
• W2980814527 hasRelatedWork W2587586746 @default.
• W2980814527 hasRelatedWork W2587702152 @default.
• W2980814527 hasRelatedWork W2901915132 @default.
• W2980814527 hasRelatedWork W2903059471 @default.
• W2980814527 hasRelatedWork W2956922957 @default.
• W2980814527 hasRelatedWork W2979358707 @default.
• W2980814527 hasRelatedWork W3092475619 @default.
• W2980814527 hasRelatedWork W3105274064 @default.
• W2980814527 hasRelatedWork W3154427589 @default.
• W2980814527 hasRelatedWork W3203002132 @default.
• W2980814527 hasRelatedWork W3213094971 @default.
• W2980814527 hasRelatedWork W3214627892 @default.
• W2980814527 isParatext "false" @default.
• W2980814527 isRetracted "false" @default.
• W2980814527 magId "2980814527" @default.
• W2980814527 workType "article" @default.